drugset / Trial / NCT06371274

A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.

NCT06371274

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the clinical efficacy and safety of oral all-trans retinoic acid in combination with toripalimab in patients with locally advanced, recurrent, or metastatic triple-negative breast cancer who had failed second-line and subsequent therapy.

Timeline

Start
2024-10-10
Primary completion
2026-04-30
Completion
2026-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Toripalimab Monoclonal antibody 240 mg Intravenous
Subject Tretinoin Small molecule 150 mg/m2 Oral